ASCO-Update 2006 - Neuigkeiten vom 42. Meeting der American Society of Clinical Oncology/ASCO 2006

Reinacher-Schick, A.; Arnold, D.; Lordick, Florian; Möhler, Markus; Lutz, Manfred P.; Seufferlein, T

doi:10.1055/s-2006-927142

Cited by 2 publications

(2 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some trials the PFS even exceeded 12 months, which is a remarkable finding [2]. OS in mCRC was significantly improved by the introduction of bevacizumab (23.6 vs. 18.6 months for standard chemotherapy alone; p < 0.001) [3].…”

Section: Efficacy In Various Cancer Typesmentioning

confidence: 99%

VEGF and EGFR inhibition: opening a new door to cancer treatment

et al. 2010

View full text Add to dashboard Cite

Zusammenfassung. Zielgerichtete Therapien sind die ersten Substanzen, mit denen bei metastasiertem Kolonkarzinom Resistenzen gegen Chemotherapien über-wunden werden können, und ermöglichen bei Lungenkarzinom bisher unerreichte Ü berlebensraten. Bis dato wurden der VEGF-Hemmer Bevacizumab und die EGFR-Inhibitoren Cetuximab, Panitumumab, Gefitinib und Erlotinib in verschiedenen klinischen Settings erforscht. Bevacizumab zeigt vielversprechende Ergebnisse in der Therapie des Mammakarzinoms, des kolorektalen Karzinoms und des Nierenzellkarzinoms. Cetuximab, Gefitinib und Erlotinib stellen bei nicht-kleinzelligem Lungenkarzinom Behandlungsoptionen dar. Patienten mit metastasiertem kolorektalen Karzinom können maßgeblich von einer Therapie mit Cetuximab oder Panitumumab profitieren. Allerdings spielt die Patientenselektion eine entscheidende Rolle, da individuelle Merkmale wie der KRAS-Mutationsstatus das Ansprechen auf die Therapie beeinflussen können. Im Rahmen der Jahrestagung der Ö sterreichischen Gesellschaft für Chirurgische Onkologie in St. Wolfgang, Ö sterreich, präsentierten Experten im Oktober 2009 die aktuelle Situation.Summary. Targeted therapies have provided the first agents that can overcome resistance to chemotherapy in metastatic colorectal cancer and have allowed for unprecedented survival rates in lung cancer. To date, the use of the VEGF inhibitor bevacizumab and the EGFR inhibitors cetuximab, panitumumab, gefitinib and erlotinib have been explored in various clinical settings. Bevacizumab has shown promising results in the treatment of breast cancer, colorectal carcinoma and renal cell carcinoma. Cetuximab, gefitinib and erlotinib are treatment options in non-small-cell lung cancer. Patients with metastatic colorectal cancer can derive great benefit from cetuximab or panitumumab therapy. However, patient selection is essential, since individual characteristics, such as KRAS mutation status, can determine response to treatment. Experts presented the current situation at the Annual Meeting of the

show abstract

Section: Efficacy In Various Cancer Typesmentioning

confidence: 99%

VEGF and EGFR inhibition: opening a new door to cancer treatment

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Additional data presented from the AIO 0604 trial [13] demonstrate that bevacizumab is highly active and also well tolerated for CRC patients with chemotherapy combinations like capecitabine plus irinotecan (XELIRI) or capecitabine plus oxaliplatin (XELOX). Capecitabine dose was reduced to 1800mg/m 2 daily in XELIRI+B in comparison to XELOX+B with 2000mg/m 2 daily.…”

Section: Bevacizumab In Mcrc: Fi Rst Beat/britementioning

confidence: 99%

Colorectal cancer

Eisterer

2008

memo

View full text Add to dashboard Cite

ASCO-Update 2006 - Neuigkeiten vom 42. Meeting der American Society of Clinical Oncology/ASCO 2006

Cited by 2 publications

References 56 publications

VEGF and EGFR inhibition: opening a new door to cancer treatment

VEGF and EGFR inhibition: opening a new door to cancer treatment

Colorectal cancer

Contact Info

Product

Resources

About